Clinical News
eMediNexus Coverage from: 
FDA approves pembrolizumab for advanced Merkel Cell Carcinoma
eMediNexus,  24 December 2018
remove_red_eye 527 Views
#Hematology #Oncology #Pathology and Lab Medicine

0 Read Comments                

The US Food and Drug Administration (FDA) has approved pembrolizumab (Keytruda, Merck), a programmed cell death–ligand-1 (PD-L1) inhibitor, for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma.
To continue reading this article
Sign in with Medtalks

Continue reading your article with a eMediNexus account.
Free Membership!